H.C. Wainwright raised the firm’s price target on DBV Technologies (DBVT) to $40 from $35 and keeps a Buy rating on the shares. The company’s Phase 3 VITESSE trial in 4-7 year old peanut-allergic children “represents a clear execution win that we believe materially de-risks the Viaskin program,” the analyst tells investors in a research note. The firm says the positive readout supports an application submission in the first half of 2026 and strengthens its confidence in a straightforward regulatory path.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DBVT:
- DBV Technologies Stock (DBVT) Soars as Clinical Trial Results Trigger Analyst Price Target Increases
- DBV Technologies price target raised to $48 from $42 at Cantor Fitzgerald
- Optimistic Buy Recommendation for DBV Technologies Driven by Viaskin Peanut’s Strong Clinical Results and Market Potential
- DBV Technologies price target raised to $51 from $35 at Guggenheim
- DBV Technologies price target raised to $45 from $21 at Citizens